Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drug Discovery: Overview01:26

Drug Discovery: Overview

7.2K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
7.2K
Structure-Activity Relationships and Drug Design01:28

Structure-Activity Relationships and Drug Design

467
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
467
Ligand Binding Sites02:40

Ligand Binding Sites

12.6K
Proteins are dynamic macromolecules that carry out a wide variety of essential processes; however, the activities of most proteins depend on their interactions with other molecules or ions, known as ligands.
Protein-ligand interactions are quite specific; even though numerous potential ligands surround a cellular protein at any given time, only a particular ligand can bind to that protein. Moreover, a ligand binds only to a dedicated area on the surface of the protein, known as the...
12.6K
Targets for Drug Action: Overview01:26

Targets for Drug Action: Overview

5.9K
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
5.9K
Protein-protein Interfaces02:04

Protein-protein Interfaces

12.4K
Many proteins form complexes to carry out their functions, making protein-protein interactions (PPIs) essential for an organism's survival. Most PPIs are stabilized by numerous weak noncovalent chemical forces. The physical shape of the interfaces determines the way two proteins interact. Many globular proteins have closely-matching shapes on their surfaces, which form a large number of weak bonds. Additionally, many PPIs occur between two helices or between a surface cleft and a...
12.4K
Drug-Receptor Interactions01:29

Drug-Receptor Interactions

4.7K
Drug-receptor interaction describes the binding of receptors by drugs, but not all drug-receptor interactions result in activation and tissue response. For instance, the binding of agonists activates the receptor to generate a cellular reaction, while antagonists bind to receptors without causing their activation.
Several parameters, such as the drug's affinity for its receptor and its efficacy, which is its ability to activate the receptor, determine the drug's effect on the tissue....
4.7K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Generate what you can make: achieving in-house synthesizability with readily available resources in de novo drug design.

Journal of cheminformatics·2025
Same author

QSPRpred: a Flexible Open-Source Quantitative Structure-Property Relationship Modelling Tool.

Journal of cheminformatics·2024
Same author

Diverse Hits in De Novo Molecule Design: Diversity-Based Comparison of Goal-Directed Generators.

Journal of chemical information and modeling·2024
Same author

HyperPCM: Robust Task-Conditioned Modeling of Drug-Target Interactions.

Journal of chemical information and modeling·2024
Same author

CLOOME: contrastive learning unlocks bioimaging databases for queries with chemical structures.

Nature communications·2023
Same author

A community effort in SARS-CoV-2 drug discovery.

Molecular informatics·2023
Same journal

MolPy: A Large Language Model-Friendly Toolkit for Reactive Topology Editing in Polymer Simulations.

Journal of chemical information and modeling·2026
Same journal

Molecular Mechanisms of KIT Receptor Dimerization and Oncogenic Activation Revealed by Multiscale Simulations.

Journal of chemical information and modeling·2026
Same journal

Structural and Thermodynamic Discrimination between Agonists and Antagonists of Retinoic Acid Receptor γ and the Vitamin D Receptor.

Journal of chemical information and modeling·2026
Same journal

PACEff Builder: An Efficient Platform for Constructing PACE Hybrid-Resolution Models for Molecular Dynamics Simulations of Aqueous Protein, Peptide Assembly, and Membrane Protein Systems.

Journal of chemical information and modeling·2026
Same journal

TransKla: A Local-Global Cross-Attention Based Transformer Approach for Prediction of Lysine Lactylation Sites.

Journal of chemical information and modeling·2026
Same journal

CondenSimAdapter: A Versatile Builder for Multiscale Simulations of Protein Condensates with Broad Force-Field Compatibility and Robust Dense-Phase Relaxation.

Journal of chemical information and modeling·2026
See all related articles

Related Experiment Video

Updated: May 17, 2025

Biosensor-based High Throughput Biopanning and Bioinformatics Analysis Strategy for the Global Validation of Drug-protein Interactions
08:31

Biosensor-based High Throughput Biopanning and Bioinformatics Analysis Strategy for the Global Validation of Drug-protein Interactions

Published on: December 1, 2020

4.9K

MHNfs: Prompting In-Context Bioactivity Predictions for Low-Data Drug Discovery.

Johannes Schimunek1, Sohvi Luukkonen1, Günter Klambauer1

  • 1ELLIS Unit Linz and LIT AI Lab, Institute for Machine Learning, Johannes Kepler University Linz, A-4040 Linz, Austria.

Journal of Chemical Information and Modeling
|April 30, 2025
PubMed
Summary
This summary is machine-generated.

Drug discovery faces data scarcity challenges. MHNfs, a new application, uses few-shot learning to predict molecular activity with limited data, accelerating candidate identification.

More Related Videos

Nano-Differential Scanning Fluorimetry for Screening in Fragment-based Lead Discovery
06:26

Nano-Differential Scanning Fluorimetry for Screening in Fragment-based Lead Discovery

Published on: May 16, 2021

4.7K
Author Spotlight: Streamlining Protein Target Prediction and Validation via Molecular Docking and CETSA
10:21

Author Spotlight: Streamlining Protein Target Prediction and Validation via Molecular Docking and CETSA

Published on: February 23, 2024

2.3K

Related Experiment Videos

Last Updated: May 17, 2025

Biosensor-based High Throughput Biopanning and Bioinformatics Analysis Strategy for the Global Validation of Drug-protein Interactions
08:31

Biosensor-based High Throughput Biopanning and Bioinformatics Analysis Strategy for the Global Validation of Drug-protein Interactions

Published on: December 1, 2020

4.9K
Nano-Differential Scanning Fluorimetry for Screening in Fragment-based Lead Discovery
06:26

Nano-Differential Scanning Fluorimetry for Screening in Fragment-based Lead Discovery

Published on: May 16, 2021

4.7K
Author Spotlight: Streamlining Protein Target Prediction and Validation via Molecular Docking and CETSA
10:21

Author Spotlight: Streamlining Protein Target Prediction and Validation via Molecular Docking and CETSA

Published on: February 23, 2024

2.3K

Area of Science:

  • Computational chemistry
  • Machine learning in drug discovery
  • Bioinformatics

Background:

  • Drug discovery increasingly utilizes computational and machine learning (ML) methods.
  • A significant hurdle in these approaches is the scarcity of high-quality data.
  • Addressing data limitations is crucial for advancing computational drug discovery.

Purpose of the Study:

  • To introduce MHNfs, an application designed for molecular activity prediction in low-data settings.
  • To provide an accessible tool for researchers to leverage few-shot learning in drug discovery.
  • To enable precise activity predictions using minimal known molecular data.

Main Methods:

  • Development of the MHNfs application, incorporating a state-of-the-art few-shot learning model.
  • Utilizing the MHNfs model, which demonstrated strong performance on the FS-Mol benchmark dataset.
  • Simulating real-world drug discovery scenarios by adapting PubChem bioassays into few-shot prediction tasks.

Main Results:

  • The MHNfs model achieved strong performance in few-shot activity prediction tasks.
  • The application provides an intuitive interface for users to obtain molecular activity predictions.
  • Evaluation using adapted PubChem bioassays confirmed the application's efficacy in low-data scenarios.

Conclusions:

  • MHNfs offers a streamlined and accessible solution for deploying advanced few-shot learning models.
  • The application effectively addresses the challenge of data scarcity in computational drug discovery.
  • MHNfs serves as a valuable tool for accelerating the identification of novel drug candidates.